Drugs / Venadaparib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03317743 | Aug 2017 → Dec 2020 | cancer | Idience Co., Ltd. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07269158 Comparator | Dec 2025 → Sep 2029 expected | biliary tract neoplasm | Yonsei University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Venadaparib | “Venadaparib (IDX-1197)” PMID 39945311 ↗ Feb 2025 |
| Known as | IDX-1197 | “Venadaparib (IDX-1197)” PMID 39945311 ↗ Feb 2025 |
| Action | Inhibit | “Venadaparib, a novel poly (ADP-ribose) polymerase (PARP) inhibitor” PMID 39945311 ↗ Feb 2025 |
| Route | Oral | “venadaparib orally” NCT07269158 ↗ |